Could This Dual-Hormone Jab Fast-Track Mazdutide Weight Loss?
Source PublicationScientific Publication
Primary AuthorsGao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L, GLORY-2 Trial Investigators.
How Mazdutide Weight Loss Works
Did you know your body uses chemical messengers to tell your brain when to stop eating? Instead of relying on willpower alone, scientists are testing a weekly injection that mimics two of these gut hormones simultaneously. This clinical trial evaluated how this dual-action approach affects mazdutide weight loss in adults with moderate to severe obesity, where traditional dietary programmes and exercise often need an extra boost.
The Phase 3 Trial Results
Researchers in China conducted a 60-week, double-blind trial with 461 participants to ensure unbiased results. The data revealed clear differences between the treatment and placebo groups:
- Participants on the active drug lost an average of 16.65% of their body weight, whilst the placebo group lost just 1.50%.
- An impressive 84.3% of the active group achieved a weight reduction of 5% or more.
- Gastrointestinal side effects were common, with 53.1% experiencing vomiting and 46.9% reporting nausea.
The Future of Hormone Therapy
This trial suggests that dual-hormone targeting could provide a highly effective tool for weight management. Whilst the weight loss is significant, the high rate of mild-to-moderate side effects means patients must weigh the benefits against stomach upset. Future studies may show if starting with a lower dose can make the treatment easier to tolerate.